FC Containing Polypeptides with Altered Glycosylation and Reduced Effector Function
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/EP2012/003819, filed Sep 12, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,836,813 | FC Containing Polypeptides with Altered Glycosylation and Reduced Effector Function In force · Medium confidence | Genzyme Corporation | In force | Medium confidence | ||
| US 9,790,268 | FC Containing Polypeptides with Altered Glycosylation and Reduced Effector Function In force · Medium confidence | Genzyme Corporation | In force | Medium confidence | ||
| US 12,612,458 | Anti-Alphabetatcr Antibody In force · Medium confidence | Genzyme Corporation | In force | Medium confidence | ||
| US 11,186,638 | Anti-Alphabetatcr Antibody In force · High confidence | Genzyme Corporation | In force | High confidence | ||
| US 12,503,498 | FC Containing Polypeptides with Altered Glycosylation and Reduced Effector Function In force · Medium confidence | Genzyme Corporation | In force | Medium confidence | ||
| Application 19/324,708 | Anti-Alphabetatcr Antibody Pending Not granted | Genzyme Corporation | Pending | Not granted | ||
| Application 19/387,958 | FC Containing Polypeptides with Altered Glycosylation and Reduced Effector Function Pending Not granted | Genzyme Corporation | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Genzyme Corporation.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.